In addition, EZH2 inhibitors may be effective in treating the EZB-like DLBCL patients bearing EZH2 mutations via suppressing methyltransferase activity.32 The ST2-like subtype was distinguished by mutations in SGK1, TET2, and SOCS1. 13,14,17 Predominantly GCB-DLBCL in origin, the ST2-like subtype was associated with favorable outcome. This evidence concerns the gene SGK1 and diffuse large B-cell lymphoma.